Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 27:12:874178.
doi: 10.3389/fonc.2022.874178. eCollection 2022.

Mastocytosis: Fertility and Pregnancy Management in a Rare Disease

Jacqueline Ferrari  1 , Pietro Benvenuti  1 , Elisa Bono  1   2 , Nicolas Fiorelli  1 , Chiara Elena  2
Affiliations
Review

Mastocytosis: Fertility and Pregnancy Management in a Rare Disease

Jacqueline Ferrari et al. Front Oncol. .

Abstract

Mastocytosis encompasses a subset of rare diseases, characterized by the presence and accumulation of abnormal neoplastic MC in various organ systems, including skin, bone marrow, spleen and gastrointestinal tract. Clinical manifestations are highly heterogeneous, as they result from both MC mediator release and MC organ infiltration. Both pregnancy, a lifetime dominated by huge physiological changes, and labor can provide triggers that could induce worsening of mastocytosis symptoms. On the other hand, mastocytosis has relevant implications in obstetric management and prenatal care during all the pregnancy. In this review article, current knowledge about the impact of mastocytosis on fertility and pregnancy outcome will be reviewed and discussed, with the aim to provide clinical practice guidance for the evaluation and management of pregnancy and delivery in patients with cutaneous and systemic mastocytosis.

Keywords: cutaneous mastocytosis; multidisciplinar management; myeloid neoplasms; pregnancy; systemic mastocytosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Arber DA, Orazi A, Hasserjian R. The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia. Blood (2016) 127(20):2391–405. doi: 10.1182/blood-2016-03-643544 - DOI - PubMed
    1. Miettinen M, Lasota J. KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation. Appl Immunohistochem Mol Morphol (2005) 13(3):205–20. doi: 10.1097/01.pai.0000173054.83414.22 - DOI - PubMed
    1. Valent P, Spanblöchl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, et al. . Induction of Differentiation of Human Mast Cells From Bone Marrow and Peripheral Blood Mononuclear Cells by Recombinant Human Stem Cell Factor/Kit-Ligand in Long-Term Culture. Blood (1992) 80(9):2237–45. doi: 10.1182/blood.V80.9.2237.2237 - DOI - PubMed
    1. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 Updated WHO Classification and Novel Emerging Treatment Concepts. Blood (2017) 129(11):1420–7. doi: 10.1182/blood-2016-09-731893 - DOI - PMC - PubMed
    1. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. . Pediatric Mastocytosis Is a Clonal Disease Associated With D816V and Other Activating C-KIT Mutations. J Invest Dermatol (2010) 130(3):804–15. doi: 10.1038/jid.2009.281 - DOI - PubMed

LinkOut - more resources